Summary
45 / 100 · Bulios Score
What speaks for it
- The share price is below the Bulios Fair Price.
What to watch
- Repaying its net debt would take 4.0 years of operating profit.
- It missed profit estimates 6 times in the last 8 quarters.
- Analysts expect revenue to fall by 12% this fiscal year.
- Out of every 100 USD of revenue, only 4.1 USD is left as net profit.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 63.4 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 2.3% a year over 5 years. Over the last 3 years it grew by 7.8% a year. For the next fiscal year analysts expect revenue to fall by 12%.
Growth in detailDoes it make money?
ReasonablyWhere 100 USD of revenue goes
- Cost of sales 48 USD
- Research and development 9.9 USD
- Sales and administration 33 USD
- Taxes and other 11 USD
- Net profit 4.1 USD
Net profit, industry median (Drug Manufacturers - Specialty & Generic) 10 USD
Out of every 100 USD of revenue, 4.1 USD is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 16.0 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Neutral- Buy 12
- Hold 23
- Sell 4
No analyst has published a price target.
31% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2024By product
- Product 87%
- Distribution Service 9.5%
- Product and Service, Other 2.2%
- License 1.0%
By region
- United States Segment 52%
- Europe Segment 33%
- International Markets 16%
Product brings in 87% of revenue. License grew fastest, by 7.6% a year.
Segments in detail